Cancer Letters
Volume 290, Issue 2 , Pages 148-156 , 28 April 2010

Bromelain’s activity and potential as an anti-cancer agent: Current evidence and perspectives

  • Katya Chobotova

      Affiliations

    • Wolfson College, University of Oxford, UK
    • CEPP, University Technology Malaysia, Malaysia
    • Corresponding Author InformationCorresponding author. Address: Wolfson College, Oxford OX2 6UD, UK.
    • ,
  • Ann B. Vernallis

      Affiliations

    • School of Life and Health Sciences, Aston University, UK
    • ,
  • Fadzilah Adibah Abdul Majid

      Affiliations

    • CEPP, University Technology Malaysia, Malaysia

Received 28 December 2008 ,Revised 29 July 2009 ,Accepted 3 August 2009.

References 

  1. Maurer HR. Bromelain: biochemistry, pharmacology and medical use. Cell. Mol. Life Sci. 2001;58:1234–1245
  2. Hale LP, Greer PK, Trinh CT, James CL. Proteinase activity and stability of natural bromelain preparations. Int. Immunopharmacol. 2005;5:783–793
  3. Castell JV, Friedrich G, Kuhn CS, Poppe GE. Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. Am. J. Physiol. 1997;273:G139–G146
  4. Hale LP. Proteolytic activity and immunogenicity of oral bromelain within the gastrointestinal tract of mice. Int. Immunopharmacol. 2004;4:255–264
  5. Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. An update. J. Ethnopharmacol. 1988;22:191–203
  6. Mialovyts’ka OA. Effect of phlogenzym in long-term treatment of patients with multiple sclerosis. Lik Sprava. 2003;109–113
  7. Brien S, Lewith G, Walker A, Hicks SM, Middleton D. Bromelain as a treatment for osteoarthritis: a review of clinical studies. Evid. Based Complement Alternat. Med. 2004;1:251–257
  8. Zavadova E, Desser L, Mohr T. Stimulation of reactive oxygen species production and cytotoxicity in human neutrophils in vitro and after oral administration of a polyenzyme preparation. Cancer Biother. 1995;10:147–152
  9. Eckert K, Grabowska E, Stange R, Schneider U, Eschmann K, Maurer HR. Effects of oral bromelain administration on the impaired immunocytotoxicity of mononuclear cells from mammary tumor patients. Oncol. Rep. 1999;6:1191–1199
  10. Snowden HM, Renfrew MJ, Woolridge MW. Treatments for breast engorgement during lactation. Cochrane Database Syst. Rev. 2001;CD000046
  11. Brien S, Lewith G, Walker AF, Middleton R, Prescott P, Bundy R. Bromelain as an adjunctive treatment for moderate-to-severe osteoarthritis of the knee: a randomized placebo-controlled pilot study. QJM. 2006;99:841–850
  12. Klein G, Kullich W, Schnitker J, Schwann H. Efficacy and tolerance of an oral enzyme combination in painful osteoarthritis of the hip. A double-blind, randomised study comparing oral enzymes with non-steroidal anti-inflammatory drugs. Clin. Exp. Rheumatol. 2006;24:25–30
  13. Guo R, Canter PH, Ernst E. Herbal medicines for the treatment of rhinosinusitis: a systematic review. Otolaryngol. Head Neck Surg. 2006;135:496–506
  14. Shahid SK, Turakhia NH, Kundra M, Shanbag P, Daftary GV, Schiess W. Efficacy and safety of phlogenzym – a protease formulation, in sepsis in children. J. Assoc. Physicians India. 2002;50:527–531
  15. Lotti T, Mirone V, Imbimbo C, Corrado F, Corrado G, Garofalo F, et al. Controlled clinical studies of nimesulide in the treatment of urogenital inflammation. Drugs. 1993;46(Suppl. 1):144–146
  16. Baumhackl U, Kappos L, Radue EW, Freitag P, Guseo A, Daumer M, et al. A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis. Mult. Scler. 2005;11:166–168
  17. Orsini RA. Bromelain, Plast. Reconstr. Surg. 2006;118:1640–1644
  18. Zanker KS. The use of systemic enzyme therapy in oncology. Cancer Chemother. Pharmacol. 2001;47(Suppl.):S1–S3
  19. Kalra N, Bhui K, Roy P, Srivastava S, George J, Prasad S, et al. Regulation of p53 nuclear factor kappaB and cyclooxygenase-2 expression by bromelain through targeting mitogen-activated protein kinase pathway in mouse skin. Toxicol. Appl. Pharmacol. 2008;226:30–37
  20. Baez R, Lopes MT, Salas CE, Hernandez M. In vivo antitumoral activity of stem pineapple (Ananas comosus) bromelain. Planta Med. 2007;73:1377–1383
  21. Beuth J, Braun JM. Modulation of murine tumor growth and colonization by bromelaine, an extract of the pineapple plant (Ananas comosum L.). In Vivo. 2005;19:483–485
  22. Guimaraes-Ferreira CA, Rodrigues EG, Mortara RA, Cabral H, Serrano FA, Ribeiro-dos-Santos R, et al. Antitumor effects in vitro and in vivo and mechanisms of protection against melanoma B16F10-Nex2 cells by fastuosain, a cysteine proteinase from Bromelia fastuosa. Neoplasia. 2007;9:723–733
  23. Taussig SJ, Szekerczes J, Batkin S. Inhibition of tumour growth in vitro by bromelain, an extract of the pineapple plant (Ananas comosus). Planta Med. 1985;538–539
  24. Tysnes BB, Maurer HR, Porwol T, Probst B, Bjerkvig R, Hoover F. Bromelain reversibly inhibits invasive properties of glioma cells. Neoplasia. 2001;3:469–479
  25. Juhasz B, Thirunavukkarasu M, Pant R, Zhan L, Penumathsa SV, Secor ER, et al. Bromelain induces cardioprotection against ischemia–reperfusion injury through Akt/FOXO pathway in rat myocardium. Am. J. Physiol. Heart Circ. Physiol. 2008;294:H1365–H1370
  26. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444
  27. Ferris RL, Grandis JR. NF-kappaB gene signatures and p53 mutations in head and neck squamous cell carcinoma. Clin. Cancer Res. 2007;13:5663–5664
  28. Chen F, Beezhold K, Castranova V. Tumor promoting or tumor suppressing of NF-kappa B, a matter of cell context dependency. Int. Rev. Immunol. 2008;27:183–204
  29. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer. 2007;121:2373–2380
  30. Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metast. Rev. 2007;26:525–534
  31. Bhui K, Prasad S, George J, Shukla Y. Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-kappa B against skin tumor-initiation triggering mitochondrial death pathway. Cancer Lett. 2009;
  32. Huang JR, Wu CC, Hou RC, Jeng KC. Bromelain inhibits lipopolysaccharide-induced cytokine production in human THP-1 monocytes via the removal of CD14. Immunol. Invest. 2008;37:263–277
  33. Hou RC, Chen YS, Huang JR, Jeng KC. Cross-linked bromelain inhibits lipopolysaccharide-induced cytokine production involving cellular signaling suppression in rats. J. Agric. Food Chem. 2006;54:2193–2198
  34. Strickland I, Ghosh S. Use of cell permeable NBD peptides for suppression of inflammation. Ann. Rheum. Dis. 2006;65(Suppl. 3):iii75–iii82
  35. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211–217
  36. Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 2006;97:439–447
  37. Qin Z, Blankenstein T. CD4+ T cell – mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity. 2000;12:677–686
  38. Hundsberger H, Verin A, Wiesner C, Pfluger M, Dulebo A, Schutt W, et al. TNF: a moonlighting protein at the interface between cancer and infection. Front. Biosci. 2008;13:5374–5386
  39. Desser L, Rehberger A, Kokron E, Paukovits W. Cytokine synthesis in human peripheral blood mononuclear cells after oral administration of polyenzyme preparations. Oncology. 1993;50:403–407
  40. Desser L, Rehberger A, Paukovits W. Proteolytic enzymes and amylase induce cytokine production in human peripheral blood mononuclear cells in vitro. Cancer Biother. 1994;9:253–263
  41. Barth H, Guseo A, Klein R. In vitro study on the immunological effect of bromelain and trypsin on mononuclear cells from humans. Eur. J. Med. Res. 2005;10:325–331
  42. Engwerda CR, Andrew D, Murphy M, Mynott TL. Bromelain activates murine macrophages and natural killer cells in vitro. Cell Immunol. 2001;210:5–10
  43. Onken JE, Greer PK, Calingaert B, Hale LP. Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro. Clin. Immunol. 2008;126:345–352
  44. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 2005;83:876–886
  45. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K, et al. RAGE signaling sustains inflammation and promotes tumor development. J. Exp. Med. 2008;205:275–285
  46. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr. Mol. Med. 2007;7:777–789
  47. Schleicher ED, Bierhaus A, Haring HU, Nawroth PP, Lehmann R. Chemistry and pathobiology of advanced glycation end products. Contrib. Nephrol. 2001;1–9
  48. Stopper H, Schinzel R, Sebekova K, Heidland A. Genotoxicity of advanced glycation end products in mammalian cells. Cancer Lett. 2003;190:151–156
  49. Abe R, Yamagishi S. AGE–RAGE system and carcinogenesis. Curr. Pharm. Des. 2008;14:940–945
  50. Makrydimas G, Zagorianakou N, Zagorianakou P, Agnantis NJ. CD44 family and gynaecological cancer. In Vivo. 2003;17:633–640
  51. Subramaniam V, Gardner H, Jothy S. Soluble CD44 secretion contributes to the acquisition of aggressive tumor phenotype in human colon cancer cells. Exp. Mol. Pathol. 2007;83:341–346
  52. Mayer S, Zur Hausen A, Watermann DO, Stamm S, Jager M, Gitsch G, et al. Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients. J. Cancer Res. Clin. Oncol. 2008;134:1229–1235
  53. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin. Cancer Biol. 2008;18:260–267
  54. Hale LP, Haynes BF. Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CD8, and Leu 8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation. J. Immunol. 1992;149:3809–3816
  55. Hale LP, Greer PK, Sempowski GD. Bromelain treatment alters leukocyte expression of cell surface molecules involved in cellular adhesion and activation. Clin. Immunol. 2002;104:183–190
  56. Kleef R, Delohery TM, Bovbjerg DH. Selective modulation of cell adhesion molecules on lymphocytes by bromelain protease 5. Pathobiology. 1996;64:339–346
  57. Munzig E, Eckert K, Harrach T, Graf H, Maurer HR. Bromelain protease F9 reduces the CD44 mediated adhesion of human peripheral blood lymphocytes to human umbilical vein endothelial cells. FEBS Lett. 1994;351:215–218
  58. Secor ER, Singh A, Guernsey LA, McNamara JT, Zhan L, Maulik N, et al. Bromelain treatment reduces CD25 expression on activated CD4+ T cells in vitro. Int. Immunopharmacol. 2009;9:340–346
  59. Fitzhugh DJ, Shan S, Dewhirst MW, Hale LP. Bromelain treatment decreases neutrophil migration to sites of inflammation. Clin. Immunol. 2008;128:66–74
  60. Massague J. TGFbeta in Cancer. Cell. 2008;134:215–230
  61. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer. 2006;6:506–520
  62. Desser L, Holomanova D, Zavadova E, Pavelka K, Mohr T, Herbacek I. Oral therapy with proteolytic enzymes decreases excessive TGF-beta levels in human blood. Cancer Chemother. Pharmacol. 2001;47(Suppl.):S10–S15
  63. Lauer D, Muller R, Cott C, Otto A, Naumann M, Birkenmeier G. Modulation of growth factor binding properties of alpha2-macroglobulin by enzyme therapy. Cancer Chemother. Pharmacol. 2001;47(Suppl.):S4–S9
  64. Rose B, Herder C, Loffler H, Meierhoff G, Schloot NC, Walz M, et al. Dose-dependent induction of IL-6 by plant-derived proteases in vitro. Clin. Exp. Immunol. 2006;143:85–92
  65. Brakebusch M, Wintergerst U, Petropoulou T, Notheis G, Husfeld L, Belohradsky BH, et al. Bromelain is an accelerator of phagocytosis, respiratory burst and killing of Candida albicans by human granulocytes and monocytes. Eur. J. Med. Res. 2001;6:193–200
  66. Fialkow L, Wang Y, Downey GP. Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Radical Biol. Med. 2007;42:153–164
  67. Wu WS, Wu JR, Hu CT. Signal cross talks for sustained MAPK activation and cell migration: the potential role of reactive oxygen species. Cancer Metast. Rev. 2008;27:303–314
  68. Roessner A, Kuester D, Malfertheiner P, Schneider-Stock R. Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol. Res. Pract. 2008;204:511–524
  69. Klink M, Jastrzembska K, Nowak M, Bednarska K, Szpakowski M, Szyllo K, et al. Ovarian cancer cells modulate human blood neutrophils response to activation in vitro. Scand. J. Immunol. 2008;68:328–336
  70. Hale LP, Fitzhugh DJ, Staats HF. Oral immunogenicity of the plant proteinase bromelain. Int. Immunopharmacol. 2006;6:2038–2046
  71. Kuester D, Lippert H, Roessner A, Krueger S. The cathepsin family and their role in colorectal cancer. Pathol. Res. Pract. 2008;204:491–500
  72. Biggerstaff JP, Weidow B, Dexheimer J, Warnes G, Vidosh J, Patel S, et al. Soluble fibrin inhibits lymphocyte adherence and cytotoxicity against tumor cells: implications for cancer metastasis and immunotherapy. Clin. Appl. Thromb. Haemost. 2008;14:193–202
  73. Lipinski B, Egyud LG. Resistance of cancer cells to immune recognition and killing. Med. Hypotheses. 2000;54:456–460
  74. Gieseler F, Luhr I, Kunze T, Mundhenke C, Maass N, Erhart T, et al. Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy. Thromb. Haemost. 2007;97:1023–1030
  75. Felton GE. Fibrinolytic and antithrombotic action of bromelain may eliminate thrombosis in heart patients. Med. Hypotheses. 1980;6:1123–1133
  76. McNicol A, Israels SJ. Beyond hemostasis: the role of platelets in inflammation, malignancy and infection. Cardiovasc. Hematol. Disord. Drug Targets. 2008;8:99–117
  77. Xiao H, Yang CS. Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. Int. J. Cancer. 2008;123:983–990
  78. Crew KD, Neugut AI. Aspirin and NSAIDs: effects in breast and ovarian cancers. Curr. Opin. Obstet. Gynecol. 2006;18:71–75
  79. Akl EA, Muti P, Schunemann HJ. Anticoagulation in patients with cancer: an overview of reviews. Pol. Arch. Med. Wewn. 2008;118:183–193
  80. Lecumberri R, Paramo JA, Rocha E. Anticoagulant treatment and survival in cancer patients. The evidence from clinical studies. Haematologica. 2005;90:1258–1266
  81. Heinicke RM, van der Wal L, Yokoyama M. Effect of bromelain (Ananase) on human platelet aggregation. Experientia. 1972;28:844–845
  82. Metzig C, Grabowska E, Eckert K, Rehse K, Maurer HR. Bromelain proteases reduce human platelet aggregation in vitro, adhesion to bovine endothelial cells and thrombus formation in rat vessels in vivo. In Vivo. 1999;13:7–12
  83. Glaser D, Hilberg T. The influence of bromelain on platelet count and platelet activity in vitro. Platelets. 2006;17:37–41
  84. Morita AH, Uchida DA, Taussig SJ, Chou SC, Hokama Y. Chromatographic fractionation and characterization of the active platelet aggregation inhibitory factor from bromelain. Arch. Int. Pharmacodyn. Ther. 1979;239:340–350
  85. Adamietz IA, Kurfurst F, Muller U, Renner K, Rimpler M. Growth acceleration of Ehrlich ascites tumor cells treated by proteinase in vitro. Eur. J. Cancer Clin. Oncol. 1989;25:1837–1841

PII: S0304-3835(09)00521-7

doi: 10.1016/j.canlet.2009.08.001

Cancer Letters
Volume 290, Issue 2 , Pages 148-156 , 28 April 2010

Article Tools